Lexeo Therapeutics, Inc.’s (NASDAQ:LXEO) Lock-Up Period Will End on May 1st

Lexeo Therapeutics’ (NASDAQ:LXEO) lock-up period will end on Wednesday, May 1st. Lexeo Therapeutics had issued 9,090,910 shares in its initial public offering on November 3rd. The total size of the offering was $100,000,010 based on an initial share price of $11.00. After the expiration of Lexeo Therapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Lexeo Therapeutics Trading Down 2.7 %

LXEO stock opened at $12.16 on Friday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. Lexeo Therapeutics has a 1 year low of $9.00 and a 1 year high of $22.33. The company has a fifty day moving average of $14.37.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its earnings results on Monday, March 11th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.15). Equities analysts anticipate that Lexeo Therapeutics will post -3.03 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LXEO. Blackstone Inc. acquired a new position in shares of Lexeo Therapeutics during the fourth quarter valued at $9,342,000. Omega Fund Management LLC acquired a new position in shares of Lexeo Therapeutics during the fourth quarter valued at $28,955,000. Finally, Eventide Asset Management LLC acquired a new position in Lexeo Therapeutics during the fourth quarter worth about $40,298,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations.